Annual report pursuant to Section 13 and 15(d)

Composition of Certain Financial Statement Captions (Details 1)

v3.3.1.900
Composition of Certain Financial Statement Captions (Details 1) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2015
Aug. 31, 2015
May. 31, 2015
Dec. 31, 2014
 [1]
Dec. 31, 2013
Fair values assigned to major intangible asset classes upon each acquisition          
Goodwill $ 743,348 [1]     $ 224,292 $ 226,373
Product registrations          
Fair values assigned to major intangible asset classes upon each acquisition          
Weighted average amortization period 9 years        
Covenants not to compete          
Fair values assigned to major intangible asset classes upon each acquisition          
Weighted average amortization period 5 years        
Bio-Reference Laboratories, Inc.          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets $ 528,300 $ 542,900      
Goodwill $ 441,158 441,158      
Bio-Reference Laboratories, Inc. | Technologies          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets   100,600      
Bio-Reference Laboratories, Inc. | Customer relationships          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets   395,200      
Bio-Reference Laboratories, Inc. | Covenants not to compete          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets   0      
Bio-Reference Laboratories, Inc. | Trade names          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets   47,100      
Weighted average amortization period 5 years        
Bio-Reference Laboratories, Inc. | Other          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets   $ 0      
CURNA          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets $ 10,290        
Goodwill 4,827        
CURNA | In-process research and development          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 10,000        
CURNA | Other          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 290        
EirGen Pharma Limited          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets     $ 38,634    
Goodwill     83,373    
EirGen Pharma Limited | In-process research and development          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets     560    
EirGen Pharma Limited | Customer relationships          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets     34,155    
EirGen Pharma Limited | Other          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets     $ 3,919    
FineTech          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 18,800        
Goodwill 11,623        
FineTech | Technologies          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 2,700        
FineTech | Customer relationships          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 14,200        
FineTech | Covenants not to compete          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 1,500        
FineTech | Trade names          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 400        
OPKO Biologics          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 590,200        
Goodwill 139,784        
OPKO Biologics | In-process research and development          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 590,200        
OPKO Biologics | Other          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 0        
OPKO Chile          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 10,806        
Goodwill 5,441        
OPKO Chile | Customer relationships          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 3,945        
OPKO Chile | Product registrations          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 5,829        
OPKO Chile | Trade names          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 1,032        
OPKO Diagnostics          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 44,400        
Goodwill 17,977        
OPKO Diagnostics | Technologies          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 44,400        
OPKO Health Europe          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 8,378        
Goodwill 8,062        
OPKO Health Europe | Technologies          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 3,017        
OPKO Health Europe | In-process research and development          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 1,459        
OPKO Health Europe | Customer relationships          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 436        
OPKO Health Europe | Product registrations          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 2,930        
OPKO Health Europe | Covenants not to compete          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 187        
OPKO Health Europe | Trade names          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 349        
OPKO Lab          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 14,030        
Goodwill 29,629        
OPKO Lab | Technologies          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 1,370        
OPKO Lab | Customer relationships          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 3,860        
OPKO Lab | Covenants not to compete          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 6,900        
OPKO Lab | Trade names          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 1,830        
OPKO Lab | Other          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 70        
OPKO Renal          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 191,740        
Goodwill 2,411        
OPKO Renal | In-process research and development          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets 191,530        
OPKO Renal | Other          
Fair values assigned to major intangible asset classes upon each acquisition          
Total identified intangible assets $ 210        
Minimum | Technologies          
Fair values assigned to major intangible asset classes upon each acquisition          
Weighted average amortization period 8 years        
Minimum | Customer relationships          
Fair values assigned to major intangible asset classes upon each acquisition          
Weighted average amortization period 6 years        
Minimum | Trade names          
Fair values assigned to major intangible asset classes upon each acquisition          
Weighted average amortization period 4 years        
Minimum | Other          
Fair values assigned to major intangible asset classes upon each acquisition          
Weighted average amortization period 3 years        
Minimum | Bio-Reference Laboratories, Inc. | Customer relationships          
Fair values assigned to major intangible asset classes upon each acquisition          
Weighted average amortization period 10 years        
Maximum | Technologies          
Fair values assigned to major intangible asset classes upon each acquisition          
Weighted average amortization period 12 years        
Maximum | Customer relationships          
Fair values assigned to major intangible asset classes upon each acquisition          
Weighted average amortization period 20 years        
Maximum | Trade names          
Fair values assigned to major intangible asset classes upon each acquisition          
Weighted average amortization period 5 years        
Maximum | Other          
Fair values assigned to major intangible asset classes upon each acquisition          
Weighted average amortization period 10 years        
Maximum | Bio-Reference Laboratories, Inc. | Customer relationships          
Fair values assigned to major intangible asset classes upon each acquisition          
Weighted average amortization period 20 years        
[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 4. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.